Sugi Predict
/ Targets
/ GAK
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to GAK by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt |
PHASE4 | COMPLETED |
| A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) |
PHASE3 | COMPLETED |
| Effect of Silymarin in Metastatic Colorectal Cancer Patients |
PHASE3 | UNKNOWN |
| The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study |
PHASE3 | RECRUITING |
| BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease |
PHASE3 | RECRUITING |
| TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer |
PHASE2 | UNKNOWN |
| Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors |
PHASE1/PHASE2 | RECRUITING |
| Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer |
PHASE2 | COMPLETED |
| Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer |
PHASE2 | COMPLETED |
| CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO |
PHASE2 | COMPLETED |
| NEOadjuvant Abemaciclib and GIredestrant TriaL in Patients with ER-positive, HER2-negative Early Breast Cancer |
PHASE2 | RECRUITING |
| Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC. |
PHASE2 | COMPLETED |
| Study of AVZO-021 in Patients With Advanced Solid Tumors |
PHASE1/PHASE2 | RECRUITING |
| Histology-Independent Study of Palbociclib in Patients With Advanced Cancer |
PHASE2 | WITHDRAWN |
| CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy |
PHASE2 | COMPLETED |
| Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer |
PHASE2 | RECRUITING |
| Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19 |
PHASE2 | UNKNOWN |
| A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers |
PHASE1 | COMPLETED |
| TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy |
PHASE1 | RECRUITING |
| AZD1775 for Advanced Solid Tumors |
PHASE1 | COMPLETED |
| Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors |
PHASE1 | COMPLETED |
| FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer |
PHASE1 | RECRUITING |
| Implementing Patients´ Competence in Oral Breast Cancer Therapy |
nan | UNKNOWN |
| Incidence of Venous Thromboembolism and Cardiovascular Events in Breast Cancer Patients Undergoing Cyclin-dependent Kinase 4/6 Inhibitors: The Breast Cancer Associated Vascular Events During Cyclin-dependent Kinase 4/6 Inhibitors Therapy (BRAVE-Cyclin) Study |
nan | ACTIVE_NOT_RECRUITING |
| Co'Moon for Supporting Breast Cancer Patients on Adjuvant Endocrine Therapy |
nan | COMPLETED |
| Outcome of Tucidinostat-Based Therapy in HR+ Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitor |
nan | UNKNOWN |
| Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period |
nan | UNKNOWN |
| Telenursing for the Early Detection and Management of Side Effects Associated With Cyclin-Dependent Kinase Inhibitors in Breast Cancer Patients |
nan | RECRUITING |
Related proteins — ESM-2 sequence neighbours (a GAK binder may also engage these)